2025-03-12 11:06:18
Latest Post
W S Industries India Ltd's subsidiary to acquire 54.89 acres land for Rs. 46.66 crores
IKS Health wins Top Honors in 2025 Black Book Survey in New AI-Driven RCM Category
Mipco Seamless Rings Gujarat Ltd approves shifting of registered office
Crizac Limited gets Sebi Nod for Rs 1,000 cr IPO
REC Limited inaugurates REC Experience Center
Stock Report
Tatva Chintan Pharma Chem Ltd consolidated Q2FY24 PAT at Rs. 7.78 crores
Posted On : 2023-11-03 13:50:58( TIMEZONE : IST )
Tatva Chintan Pharma Chem Ltd has reported Consolidated financial results for the period ended September 30, 2023.
Financial Results (Q2 FY2024) - QoQ Comparison
The company has reported total income of Rs. 97.425 crores during the period ended September 30, 2023 as compared to Rs. 115.379 crores during the period ended June 30, 2023.
The company has posted net profit / (loss) of Rs. 7.781 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs. 9.504 crores for the period ended June 30, 2023.
The company has reported EPS of Rs. 3.43 for the period ended September 30, 2023 as compared to Rs. 4.29 for the period ended June 30, 2023.
| Financials | Q2 FY2024 | Q1 FY2024 | % Change |
| Total Income | ₹ 97.425 crs | ₹115.379 crs |  -15.56% |
| Net Profit | ₹7.781 crs | ₹9.504 crs | -18.13% |
| EPS | ₹3.43 | ₹4.29 | -20.05% |
Financial Results (Q2 FY2024) - YoY Comparison
The company has reported total income of Rs. 97.425 crores during the period ended September 30, 2023 as compared to Rs.92.037 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.7.781 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs.7.111 crores for the period ended September 30, 2022.
The company has reported EPS of Rs.3.43 for the period ended September 30, 2023 as compared to Rs.3.21 for the period ended September 30, 2022.
| Financials | Q2 FY2024 | Q2 FY2023 | % Change |
| Total Income | ₹ 97.425 crs | ₹92.037 crs |  5.85% |
| Net Profit | ₹7.781 crs | ₹7.111 crs | 9.42% |
| EPS | ₹3.43 | ₹3.21 | 6.85% |
Financial Results (Half Year Ended FY2024) - YoY Comparison
The company has reported total income of Rs.212.804 crores during the 6 Months period ended September 30, 2023 as compared to Rs.182.315 crores during the 6 Months period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.17.285 crores for the 6 Months period ended September 30, 2023 as against net profit / (loss) of Rs.16.909 crores for the 6 Months period ended September 30, 2022.
The company has reported EPS of Rs.7.72 for the 6 Months period ended September 30, 2023 as compared to Rs.7.63 for the 6 Months period ended September 30, 2022.
| Financials | Half Year Ended FY2024 | Half Year Ended FY2023 | % Change |
| Total Income | ₹212.804 crs | ₹182.315 crs | 16.72% |
| Net Profit | ₹17.285 crs | ₹16.909 crs | 2.22% |
| EPS | ₹7.72 | ₹7.63 | 1.18% |
Shares of Tatva Chintan Pharma Chem Ltd was last trading in BSE at Rs. 1437.05 as compared to the previous close of Rs. 1450.00. The total number of shares traded during the day was 2740 in over 880 trades.
The stock hit an intraday high of Rs. 1474.20 and intraday low of 1425.00. The net turnover during the day was Rs. 3964270.00.
